$IMLFF recent news: InMed Pharmaceuticals Appoints
Post# of 35486
(Total Views: 110)
Posted On: 01/18/2017 8:49:57 AM
$IMLFF recent news: InMed Pharmaceuticals Appoints Martin Bott to Board of Directors
http://finance.yahoo.com/news/inmed-pharmaceu...00273.html
VANCOUVER, Jan. 13, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed" (CSE: IN; OTCQB: IMLFF), today announced that Martin Bott, VP of Corporate Finance and Investment Banking at Eli Lilly & Company, has been appointed to InMed Board of Directors effective immediately. Mr. Bott brings over 28 years of senior financial and executive leadership to InMed's Board of Directors.
"Martin Bott has established a significant leadership position in financial and business expertise with one of the world's leading pharmaceutical companies. His depth of knowledge in navigating the complexities in healthcare finance and operations on a global level will be invaluable to InMed," said Eric A. Adams, President & Chief Executive Officer. "We welcome Martin to our Board and look forward to his strategic counsel as we work towards achieving our many corporate objectives."
Mr. Bott has a Bachelors of Business / Marketing (Cologne, Germany, 1985) and a Master's in International Business Studies (University of South Carolina, 1988). He joined Lilly in 1988 and has held roles of increasing responsibility at their headquarters in Indianapolis as well as affiliates in Switzerland, Germany, and the UK. Prior to his current assignment, Mr. Bott was the CFO for both the Diabetes Business and the Global Manufacturing and Quality organizations. He has been a member of the Lilly CFO Staff since December 2002.
"I am delighted to be joining InMed as a Board Member," stated Mr. Bott. "InMed is at a pivotal point in its evolution. Its broad base of assets, from the drug development pipeline to the cannabinoid biosynthesis and other enabling technologies, will require careful planning and execution. I look forward to working with the other Directors and executive team to contributing to the achievement of InMed's strategic initiatives and future growth."
http://finance.yahoo.com/news/inmed-pharmaceu...00273.html
VANCOUVER, Jan. 13, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed" (CSE: IN; OTCQB: IMLFF), today announced that Martin Bott, VP of Corporate Finance and Investment Banking at Eli Lilly & Company, has been appointed to InMed Board of Directors effective immediately. Mr. Bott brings over 28 years of senior financial and executive leadership to InMed's Board of Directors.
"Martin Bott has established a significant leadership position in financial and business expertise with one of the world's leading pharmaceutical companies. His depth of knowledge in navigating the complexities in healthcare finance and operations on a global level will be invaluable to InMed," said Eric A. Adams, President & Chief Executive Officer. "We welcome Martin to our Board and look forward to his strategic counsel as we work towards achieving our many corporate objectives."
Mr. Bott has a Bachelors of Business / Marketing (Cologne, Germany, 1985) and a Master's in International Business Studies (University of South Carolina, 1988). He joined Lilly in 1988 and has held roles of increasing responsibility at their headquarters in Indianapolis as well as affiliates in Switzerland, Germany, and the UK. Prior to his current assignment, Mr. Bott was the CFO for both the Diabetes Business and the Global Manufacturing and Quality organizations. He has been a member of the Lilly CFO Staff since December 2002.
"I am delighted to be joining InMed as a Board Member," stated Mr. Bott. "InMed is at a pivotal point in its evolution. Its broad base of assets, from the drug development pipeline to the cannabinoid biosynthesis and other enabling technologies, will require careful planning and execution. I look forward to working with the other Directors and executive team to contributing to the achievement of InMed's strategic initiatives and future growth."
(0)
(0)Scroll down for more posts ▼